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Abstract
 
Angiogenesis, the sprouting of new capillaries from preexisting blood vessels, results from a dis-
ruption of the balance between stimulatory and inhibitory factors. Here, we show that anoxia
reduces expression of thrombospondin-1 (TSP-1), a natural inhibitor of angiogenesis, in glio-
blastoma cells. This suggests that reduced oxygen tension can promote angiogenesis not only
by stimulating the production of inducers, such as vascular endothelial growth factor, but also
by reducing the production of inhibitors. This downregulation may significantly contribute to
glioblastoma development, since we show that an increase in TSP-1 expression is sufficient to
strongly suppress glioblastoma cell tumorigenicity in vivo.
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Introduction
 
Glioblastoma is the most frequent human primary brain tu-
mor and represents the ultimate and most malignant stage
of astrocytoma progression. This progression is accompa-
nied by a sequential series of genetic alterations including
 
mutation or loss of the 
 
TP53
 
 gene on chromosome 17p (1)
and the 
 
PTEN
 
 gene on chromosome 10q (2, 3).
Malignant astrocytomas are among the most vascularized
human tumors, suggesting that angiogenesis is a crucial
event during their genesis. Despite this prominent vascular-
ization, the supply of oxygen and nutrients seems to be in-
sufficient to support such rapidly expanding tumors, and
necrosis appears (4). The switch to the angiogenic pheno-
type of a tumor is thought to result from a shift in the bal-
ance between the secretion of angiogenesis inducers and
inhibitors. Glioblastoma cells secrete many angiogenic fac-
tors, including acidic and basic fibroblast growth factors
 
(aFGF and bFGF)
 
1
 
 (5), IL-8 (6), and especially vascular en-
dothelial growth factor (VEGF), which is a specific endo-
thelial cell mitogen (7, 8).
Both the physiological changes that gradually develop
during malignant progression of astrocytoma and the ge-
netic alterations arising during this evolution are able to af-
fect the neovascularization of this tumor type. Physiological
regulation of angiogenesis in astrocytoma is mediated
through stimulation by angiogenic factors. VEGF and IL-8
expression is induced in cells lining necrotic tumor areas
where hypoxia upregulates their mRNA levels (7–10). Ge-
netic alterations can affect both angiogenic stimulators and
inhibitors in glioblastoma. Wild-type (wt) p53 has been
demonstrated to repress the 
 
bFGF
 
 gene, while mutant
forms of the protein can activate it in vitro (11). Loss of
p53 function may also cause an increase in VEGF levels, as
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Abbreviations used in this paper:
 
 aFGF, acidic fibroblast growth factor;
bFGF, basic fibroblast growth factor; GD-AIF, glioma-derived angiogen-
esis inhibitory factor; TIMP-1, tissue inhibitor of metalloproteinase 1;
TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor;
wt, wild-type.
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p53 has been suggested to negatively regulate VEGF ex-
pression in glioma cells (12). Furthermore, p53-null glio-
blastoma cells are able to release an inhibitor of angiogene-
sis, called glioma-derived angiogenesis inhibitory factor
(GD-AIF), upon restoration of wt p53 function (13). p53
was also shown to positively regulate the expression of
thrombospondin-1 (TSP-1), a physiological inhibitor of
angiogenesis, in fibroblasts of Li-Fraumeni patients (14). It
is unclear whether p53 also controls TSP-1 expression in
glioblastoma and whether TSP-1 and GD-AIF are identi-
cal. TSP-1 expression is also upregulated by a potential tu-
mor suppressor gene(s) on chromosome 10 that is lost dur-
ing the final progression to glioblastoma (15).
TSP-1 is a 450-kD homotrimeric extracellular matrix
glycoprotein. It has a complex structure and modulates cel-
lular behaviors like motility, adhesion, and proliferation
that are important for tumor growth and metastasis (16,
17). Furthermore, TSP-1 has been shown to inhibit angio-
genesis both in vitro by inhibiting endothelial cell prolifer-
ation, migration, and cord formation (18–21) and in vivo,
in the rat cornea (18). In addition, peptides from TSP-1
type 1 properdin repeats can compete with bFGF for bind-
ing to endothelial cells and prevent their bFGF-induced
proliferation and migration (22). Both intact TSP-1 and
derived peptides have been shown to induce apoptosis in
endothelial cells (23). The in vitro antiangiogenic activity
of TSP-1 has been demonstrated to be mediated by the
CD36 receptor expressed on endothelial cells (24).
Here, we wished to examine whether TSP-1 is regulated
by p53 in glioblastoma, whether a decrease in oxygen ten-
sion as occur in tumors could alter its expression, and
whether increase in TSP-1 levels would affect glioblastoma
tumorigenesis.
 
Materials and Methods
 
Cell Culture and Anoxic and Cobalt Chloride Treatments.
 
Glio-
blastoma cells were grown in DME supplemented with 5% FCS
and subjected to anoxia as described (9). Cobalt chloride treat-
ment was performed by incubating LN-229 cells with cobalt
chloride at different concentrations (100, 200, and 400 
 
m
 
M) for
24 h. Fresh culture medium was added at the beginning of incu-
bation. At time zero, RNA extraction was performed immedi-
ately after medium change.
 
Northern Blot Analysis.
 
Northern blot analysis was done as
previously described (9) with 10 
 
m
 
g of total RNA. 18S rRNA
was stained by immersing the membrane in 0.02% methylene
blue, 0.3 M sodium acetate, pH 5.5, for 45 s. The membrane was
then destained in water for 3–4 min, photocopied, and com-
pletely destained in 0.2
 
3 
 
SSC, 1% SDS for 15 min. The probes
used were a 1.4-Kb BamHI fragment of the human TSP-1
cDNA from plasmid pcDNATS1 (25), a 1.8-Kb BamHI frag-
ment of human p53 cDNA from plasmid pc53SN3, a 1-Kb
NotI–EcoRI fragment of human CDKN1 cDNA from plasmid
pCEP-WAF1-S (26), a 0.5-Kb EcoRI–BamHI fragment of hu-
man VEGF cDNA from plasmid pBspt-KS-VEGF165 (10), and a
0.6-Kb EcoRI–KpnI fragment of human tissue inhibitor of me-
talloproteinase (TIMP)-1 cDNA from plasmid pBSTIMP1 (pro-
vided by W.G. Stetler-Stevenson, National Cancer Institute, Be-
 
thesda, MD). The probe for fibronectin was synthesized by
reverse transcriptase PCR on total RNA from LN-229 cells using
primers 5
 
9
 
-GGCGACAGGACGGACATCTTTGGT-3
 
9
 
 (for-
ward) and 5
 
9
 
-ATGCTGATGAGCTGGCCCTCGTATAC-3
 
9
 
(reverse). After 3 min of initial denaturation, 35 cycles of amplifi-
cation were performed at 95
 
8
 
C for 60 s (denaturation) and 70
 
8
 
C
for 90 s (annealing and elongation).
 
Immunoprecipitation.
 
Immunoprecipitations were performed
as previously described on cellular extracts (27). The mAbs used
were G59-12 (PharMingen) for human p53 and clones A6.1 and
A4.1 (GIBCO BRL) for human TSP-1.
 
Western Blot Analysis.
 
Serum-free conditioned media from
1.25 
 
3 
 
10
 
5 
 
(LN-229), 8 
 
3 
 
10
 
5 
 
(U87MG), 4 
 
3 
 
10
 
4 
 
(D247MG),
and 2.6 
 
3 
 
10
 
5 
 
(LN-Z308) cells grown under normoxia or anoxia
were electrophoresed on a reducing 5% SDS–polyacrylamide gel
and then transferred onto Hybond C membranes (Amersham
Pharmacia Biotech). The blots were first incubated with a mouse
mAb against human TSP-1 (Ab-4, clone A6.1; Neomarkers) and
then with a horseradish peroxidase–conjugated anti–mouse IgG
(Sigma-Aldrich). The blots were developed with the BM chemi-
luminescence Blotting Substrate POD kit (Boehringer Mann-
heim). Western blot analysis was performed on serum-free condi-
tioned media from 10
 
5
 
 cells of the clones stably transfected with
TSP-1 cDNA (C8, C9, E7) or the cloning vector (A7, A8, A9).
 
Silver Staining.
 
Serum-free conditioned media, corresponding
to 10
 
5
 
 (U87MG, D247MG), 2.5 
 
3 
 
10
 
5 
 
(LN-Z308), and 37.5 
 
3
 
10
 
5
 
 (LN-229) cells grown under normoxia or anoxia were pre-
cipitated with TCA. Proteins were electrophoresed on a reducing
8% SDS-PAGE using ProSieve 50 acrylamide (FMC Bioprod-
ucts). Silver staining was performed using a commercial kit (Am-
ersham Pharmacia Biotech).
 
Nuclear Run-on Assays.
 
Nuclear run-on assays were previ-
ously described (10) using nuclear extracts from LN-229 cells ex-
posed to normoxia for 24 h or to anoxia for 12 and 24 h. The
plasmid DNAs deposited on the membrane contained cDNAs for
human TSP-1, human VEGF
 
165
 
, and mouse lymphocyte 
 
b
 
-actin
(10). Empty plasmid vectors, pcDNA1neo for TSP-1 and pBS for
VEGF
 
165
 
, were used as controls for nonspecific hybridization.
 
Transfection.
 
Cells were transfected with 10 
 
m
 
g of TSP-1 ex-
pression plasmid pcDNATS1 (25) or the pcDNAIneo control
vector (Invitrogen) using the calcium phosphate procedure. After
24 h, G418 (600 
 
m
 
g/ml) was added, and single clones were iso-
lated after 2–3 wk of selection.
 
ELISA.
 
Human TSP-1 purified from thrombin-activated
platelets (28) was used to generate polyclonal antibodies in rab-
bits. Specificity of this antiserum was examined by Western blot
analysis on purified human TSP-1 and bovine TSP-2. No cross-
reactivity with TSP-2 was found (not shown). 96-well micro-
plates were coated overnight at 4
 
8
 
C with 0.2 ml per well of rabbit
polyclonal anti–TSP-1 antiserum diluted 1:40 in 20 mM Tris-
HCl buffer, pH 9. Saturation of the nonspecific binding sites was
then performed by a 40-min incubation at 37
 
8
 
C in the presence
of 2% BSA in coating buffer. After two PBS washes, samples
were added to the wells and incubated for 2 h at 37
 
8
 
C under gen-
tle shaking in the presence of 2% BSA, 0.05% Tween 20, and
0.25 
 
m
 
g/ml of mouse anti–human TSP-1 mAb (Boehringer-
Mannheim). Purified human TSP-1 (0–10 ng) was used as a stan-
dard for the calibration curve. The plates were then rinsed three
times with PBS–Tween 0.05%, and 0.2 ml per well of alkaline
phosphatase–coupled goat anti–mouse IgG (Bio-Rad), diluted
1:500 in PBS–Tween 0.05%–3% BSA, was added for 40 min at
37
 
8
 
C. After seven PBS–Tween washes, the reaction was revealed
using 
 
p
 
-nitrophenyl phosphate as a substrate, and the OD at 405
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nm was measured on a microplate densitometer. The detection
limit of the assay is 0.3 ng TSP-1. The standard deviation be-
tween multiple determinations using this assay was 
 
,
 
12%. ELI-
SAs for bFGF and VEGF were performed with Quantikine Im-
munoassays (R & D Systems, Inc.).
 
Immunostaining.
 
Immunostaining for microvessels was per-
formed as previously described (29) using a biotin anti–mouse
CD31 Ab (clone MEC 13.3; PharMingen). Microvessels were
counted in a 100
 
3
 
 power field with a 5 
 
3 
 
5 grid. Only vessels
crossing the intersection points of the grid were counted. For each
tumor, five random fields were counted in a blinded manner by
three independent investigators. (M. Tenan, M.-F. Hamou, and
J.-F. Brunet [University of Lausanne, Lausanne, Switzerland]).
 
Tumorigenesis Assay.
 
For each clone, ten Swiss 
 
nu/nu
 
 6–7-
wk-old male mice were injected subcutaneously with 6 
 
3 
 
10
 
6
 
cells. Each mouse was injected with cells from a TSP-1–express-
ing clone (C8, C9, or E7) in the right flank and with a pool of
cells from control clones (A7, A8, A9) in the left flank. Tumor
sizes were measured weekly with a caliper. When mice were
killed, tumors were resected, weighed, and frozen for histological
studies. Tumor volume (mm
 
3
 
) was calculated as (length 
 
3
 
width
 
2
 
)/2.
 
Results
 
p53 Does Not Regulate TSP-1 in Glioblastoma Cells.
 
To
first establish whether TSP-1 might be related to GD-AIF
and mediate p53 control on angiogenesis, we examined
whether p53 could regulate TSP-1 expression in glioblas-
toma cells. TSP-1 expression was analyzed in LN-Z308
glioblastoma cells, where p53 can be regulated by tetracy-
cline (13).
 
 
 
Cellular TSP-1 levels were measured in two
clones conditionally inducible for p53 (wt4, wt11) in the
presence (no induction) or absence (p53 induction) of tet-
racycline and in a control clone not inducible for p53
(wt1). The amounts of immunoprecipitated TSP-1 protein
did not differ upon wt p53 induction in both wt4 and wt11
clones (Fig. 1). Moreover, Northern blotting on five glio-
blastoma cell lines with wt (U87MG, D247MG) or mutant
(LN-229, LN-319, LN-Z308) 
 
TP53
 
 alleles (30) did not
show any correlation between TSP-1 mRNA expression
and 
 
TP53
 
 gene status (data not shown).
 
To examine whether TSP-1 expression and 
 
TP53
 
 gene
status of tumor cells might correlate in vivo, we performed
immunostainings for TSP-1 on a series of 10 human WHO
grade II/grade IV astrocytoma pairs from patients with re-
currence for which we established the status of the 
 
TP53
 
gene (31). In four cases (no. 4, 7 mutant 
 
TP53
 
 and nos. 15
and 18, wt 
 
TP53
 
), tumor cells staining for TSP-1 were de-
tected in the low grade but not in the recurrent higher
grade astrocytoma. In one case (no. 2, mutant 
 
TP53
 
), posi-
tive cells were observed in the recurrent glioblastoma but
not in the initial low-grade tumor. In five cases (nos. 1, 3,
and 9, mutant 
 
TP53
 
, and nos. 16 and 25, wt 
 
TP53
 
), no
staining was observed. These observations did not correlate
with 
 
TP53
 
 gene status (data not shown).
 
TSP-1 Synthesis Is Reduced by Decreased Oxygen Tension.
 
Since variation in oxygen tension is an important factor
regulating angiogenesis mediators such as VEGF or IL-8
in glioblastoma, we explored the possibility that de-
creased oxygen could also influence TSP-1 expression.
Four glioblastoma cell lines were placed for 24–48 h in
conditions of normoxia and anoxia using anaerobic cham-
bers. By Northern blotting (Fig. 2 a) we found, as ex-
pected, an important upregulation of VEGF mRNA ex-
pression when cells were exposed to anoxia. On the
contrary, TSP-1 mRNA levels were significantly decreased
under the same conditions. Densitometric analysis revealed
a reduction of up to eightfold (D-247MG) in TSP-1
mRNA levels. The specificity of these observations was
further verified by rehybridizing with a probe for fibronec-
tin and TIMP-1, another inhibitor of angiogenesis (32).
Furthermore, no evidence for mRNA degradation was ob-
served under anoxia. Secreted TSP-1 was then examined
by Western blotting in conditioned media from the same
cell lines exposed to normoxia or anoxia (Fig. 2 b). TSP-1
levels were significantly reduced up to sevenfold (D247MG,
LN-Z308) under anoxia as compared with normoxia. This
reduction in TSP-1 levels was not likely due to protein
degradation under anoxia, as no degradation products were
observed. To examine whether reduction of protein ex-
pression was a general phenomenon under anoxia, we
compared levels of secreted proteins under anoxia and nor-
moxia by silver staining. Levels of secreted proteins were
not altered for the vast majority of proteins under anoxia. A
few large proteins showed reduced secretion (Fig. 2 c).
This was not observed on extracts of intracellular proteins
(not shown), suggesting impaired secretion of a selected
subset of large proteins under anoxia. These data suggest
that under anoxic conditions, both a reduction in TSP-1
mRNA levels and a decreased TSP-1 secretion are respon-
sible for the final decrease in released TSP-1. Due to the
combination of these mechanisms, glioblastoma cells
stressed by low oxygen tension will release high levels of
VEGF and reduced levels of TSP-1. This will result in a
strong imbalance in favor of angiogenesis stimulation.
Prolonged exposure to anoxia can induce programmed
cell death in mammalian cells (33). Therefore, we exam-
ined whether the reduction in TSP-1 mRNA and protein
levels we observed could be the consequence of an apop-
Figure 1. Immunoprecipitation of cellular p53 and TSP-1. Clones wt4
and wt11, derived from parental LN-Z308 cells, contain a wt TP53 gene
under a tetracycline-regulated promoter (1, with tet; 2, without tet). In
the wt1 clone, p53 is not induced upon tetracycline removal and served
as a negative control (13). The antibodies used were A6.1 (GIBCO BRL)
for TSP-1 and G59-13 (PharMingen) for p53. Similar results were ob-
tained with anti-TSP-1 antibody A4.1 (GIBCO BRL) (not shown).
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totic process. Morphological analysis of cells under anoxia
for up to 48 h did not reveal any signs of apoptosis. Fur-
thermore, using phosphatidylserine membrane transloca-
tion and caspase 3 activation assays, we found no significant
difference in either apoptotic or necrotic cells under anoxia
as compared with normoxia in all four cell lines analyzed
(data not shown). This suggests that the drop in TSP-1
mRNA and protein levels is not due to induction of apop-
totic cell death under anoxia. Moreover, when reoxygen-
ated after the 24-h anoxic period, the cells resumed cell
growth showing cell viability and reversibility of the anoxic
stress (not shown).
Next, we investigated whether the mechanism of TSP-1
mRNA decrease by anoxia shared characteristics of the ox-
ygen-sensing and signal transduction pathways reported for
hypoxia-inducible factors. For such factors, cell incubation
with cobalt imitates the gene induction normally mediated
 
by oxygen deprivation stress (34, 35). Therefore, two cell
lines were treated with cobalt chloride for 24 (LN-229) or
48 h (D247MG). By Northern blot analysis, we established
that the minimal concentration of cobalt chloride able to
upregulate VEGF was 400 
 
m
 
M. Precisely at this concentra-
tion, TSP-1 mRNA was significantly reduced in D247MG
cells (Fig. 2 d) and LN-229 cells (data not shown). This co-
balt concentration is not toxic to the cells and does not in-
duce apoptosis, as measured by annexin V assay and mor-
phology (not shown). After densitometric normalization
with 18S rRNA for variations in RNA loading, no varia-
tion for TIMP-1 mRNA was found. These results suggest
that treatment with cobalt can reproduce TSP-1 mRNA
reduction caused by anoxia in these cells.
To further explore whether the drop in TSP-1 mRNA
under anoxic conditions was the consequence of a direct
downregulation of TSP-1 gene transcription, a nuclear
Figure 2. (a) Northern blotting on total RNA of glioblastoma cell lines exposed for 24 or 48 h (D247MG) to normoxia (N) and anoxia (A) (LN-229,
n 5 3; LN-Z308, U87MG, and D247MG, n 5 2). cDNA probes for TSP-1, VEGF, fibronectin (FN), and TIMP-1 were used. 18S rRNA (18S) was re-
vealed with methylene blue staining. (b) Analysis of TSP-1 expression by Western blotting on 24- or 48-h (D247MG) conditioned media from glioblas-
toma cell lines exposed to normoxia (N) and anoxia (A) (n 5 3). Mouse anti–TSP-1 mAb A6.1 (Neomarkers) was used. (c) Silver staining of secreted
proteins from glioblastoma cell lines exposed to normoxia (N) and anoxia (A) for 24 and 48 h (D247MG) (n 5 5). Black arrows provide examples of large
proteins for which secretion is not affected by anoxia. Open arrows show proteins for which secretion is decreased under anoxia. Proteins from 105
(U87MG, D247MG), 2.5 3 105 (LN-Z308), and 37.5 3 105 (LN-229) cells were loaded. (d) Northern blotting on total RNA of LN-229 glioblastoma
cells treated with cobalt chloride at different concentrations (C100, 100 mM; C200, 200 mM; and C400, 400 mM) for 24 h (n 5 2). Time zero, t0 (no cobalt
treatment); normoxia for 24 h (N). (e) Nuclear run-on assay for TSP-1 mRNA from LN-229 cells. Nuclear extracts were prepared after 24 h normoxia
(N), 12 h anoxia (A12), and 24 h anoxia (A24) (n 5 2). Empty vector DNAs were used as controls (pcDNA1neo for TSP-1; pBspt-KS for VEGF). The
controls of this experiment were previously reported (10).
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run-on analysis was performed on LN-229 cells. Whereas
under anoxia an increase in VEGF transcription (29- and
20-fold at 12 and 24 h of anoxia, respectively) was ob-
served, TSP-1 and b-actin mRNA levels were not affected
as compared with normoxia (Fig. 2 e). These results indi-
cate that the decrease in TSP-1 mRNA observed under an-
oxic conditions is due to posttranscriptional events and that
the anoxic treatment applied does not induce a general
downregulation of transcription.
Clearly, further work is necessary to investigate the de-
tailed mechanism(s) responsible for TSP-1 downregulation
and establish whether, besides regulation by anoxia and co-
balt, they share other components with the biochemical
mechanisms regulating hypoxia-inducible factors such as
VEGF. It is important to stress that regardless of the mech-
anism responsible for downregulation of TSP-1 and upreg-
ulation of VEGF by anoxia, the net result in the tumor will
be that anoxia-stressed tumor cells will stay alive and con-
tinuously promote angiogenesis.
TSP-1 cDNA Transfection Can Reduce Glioblastoma
Growth. To validate the importance of a reduction in
TSP-1 levels by anoxia for tumor development, we exam-
ined whether increased TSP-1 expression can restrict tumor
growth. For this purpose, we selected LN-229 cells, which
form tumors in immunocompromised mice, and transfected
them with a human TSP-1 expression vector pcDNATS1
or the empty vector pcDNAIneo (25). Neomycin-resistant
clones were isolated and screened by PCR for TSP-1
cDNA sequence and ELISA for TSP-1 expression. Three
clones with increased TSP-1 expression (TSP-1 clones) and
three vector control clones were retained. The cells were
grown to prepare serum-free conditioned media, and the
levels of secreted TSP-1 were measured by Western blot
analysis (Fig. 3). Levels of TSP-1, bFGF, and VEGF were
also measured by ELISA (not shown). TSP-1 levels were
quite uniform among the control clones, whereas the TSP-1
clones showed two- to 28-fold increased levels of expres-
sion. Levels of secreted bFGF (7–12 pg/ml) and VEGF (0
ng/ml) were similar in control and transfected clones. The
in vitro growth rate of the clones was tested, and we did
not observe any consistent differences between control and
TSP-1 clones, nor did we see a difference in the capacity to
form colonies in soft agar (data not shown).
We then analyzed whether increased TSP-1 expression
might affect the ability of these cells to form tumors in
vivo. Three series of 10 immunodeficient nu/nu mice were
injected subcutaneously with a pool of cells from control
clones on the left side and cells from each TSP-1 clone on
the right side. Weekly size measurements showed that con-
trol clones gave rise to rapidly growing tumors, whereas
TSP-1 clones showed slower or no tumor formation (Fig.
4). After a period of 9 wk, mice had to be killed due to the
large size of control tumors and tumor weights were mea-
sured (Fig. 5 A). As expected from previous experience
with xenografting, we found a high intermouse variability
in tumor weights for control cells, demonstrating the im-
portance of injecting both control clones and test clones in
the same animals. 25 mice out of 27 showed TSP-1 tumors
smaller than controls (Student’s t test; P 5 0.0002, n 5 27).
Figure 3. Analysis of TSP-1 expression by Western blotting on serum-
free conditioned media from LN-229 clones. Medium from 105 cells was
loaded for each clone. A7, A8, A9, control clones; C8, C9, E7, TSP-1–
expressing clones. The position and size in kilodaltons of molecular mass
markers are indicated to the left. In addition to full-length TSP-1, a 160-
kD proteolytic fragment was also seen in clones C9 and E7 similar to pre-
vious observations (47). Scanning of the 180-kD bands gave the following
values: 217 (A7), 82 (A8), 131 (A9), 328 (C8), 2,396 (C9), and 4,100
(E7). The mean of the control clones is 143. Therefore, C8 shows a 2.3-
fold, C9 a 16.7-fold, and E7 a 28.6-fold increase in TSP-1 expression.
Figure 4. Tumor size measurements in mice injected with a pool of
cells from control clones (Control) and cells from individual TSP-1–
expressing clones (C8, C9, E7). 5 mice were injected for each clone in
two independent experiments (10 mice per clone total).
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These results demonstrated that a two- to 28-fold increase
in TSP-1 expression in LN-229 glioblastoma cells sup-
presses their tumorigenicity in vivo.
To verify whether the suppression of tumor growth cor-
related with a reduction in the extent of angiogenesis, tu-
mors were sectioned and examined for microvessel density.
Sections were stained with an antibody against CD31 and
microvessels were counted (Fig. 5 B). The mean vessel
density in the TSP-1 tumors was 48% of that seen in con-
trols (Student’s t test; P , 0.0001, n 5 24). Morphological
examination of the vessels revealed predominantly capillar-
ies in TSP-1 tumors and large vessels in control tumors
(Fig. 6).
Discussion
Glioblastoma is one of the most vascularized human can-
cers, and the formation of tumor-specific blood vessels oc-
curs early at the onset of tumor growth. The switch to the
angiogenic phenotype of a tumor can be related to onco-
gene activation and tumor suppressor gene loss (36). In fi-
broblasts of Li-Fraumeni patients, p53 has been shown to
regulate the expression of TSP-1 (14). In glioblastoma cells,
p53 inactivation increases bFGF and VEGF expression (11,
12), and p53 overexpression leads to the synthesis of an as
yet unidentified angiogenesis inhibitor called GD-AIF (13).
To establish whether GD-AIF and TSP-1 might be related,
we examined whether p53 could control TSP-1 expression
in glioblastoma cells. Our data suggest that TSP-1 is not
regulated by p53 in glioma and is thus unlikely to be GD-
AIF. BAI-1 (brain-specific angiogenesis inhibitor 1), a pu-
tative p53-regulated angiogenesis inhibitor, is a new candi-
date for this activity (37). Loss of TSP-1 expression in the
malignant progression of astrocytoma might occur by loss
of a positive regulator encoded on chromosome 10 (refer-
ence 15) or by downregulation of the TSP-1 gene through
methylation of its promoter (38). As LOH (loss of het-
erozygosity) on chromosome 10 is a hallmark of glioblas-
toma, this result suggests that downregulation of TSP-1 ex-
pression by genetic alteration(s) could be involved in the
transition to the last phase of malignant progression. At this
stage, the tumor vasculature reaches its ultimate and anar-
chic expansion and conditions of decreased oxygen supply
lead to necrosis.
Hypoxia/anoxia promotes angiogenesis by upregulating
the expression of angiogenic molecules. Here, we report
Figure 5. (A) Tumor weights (grams) of mice killed at 9 wk. C, control tumor; TSP-1, TSP-1 tumor. Asterisk (*), mice killed 2 wk after injection
due to extensive skin damage after mice fightings. 2, no tumor. The difference of mean tumor weight between C and TSP-1 tumors was found to be
highly significant (Student’s t test; P 5 0.0002, n 5 27). (B) Measurements of tumor microvessel density. C, control tumor; TSP-1, TSP-1 tumor. Mi-
crovessels were counted by three independent investigators. Graphic signs allow one to individually identify microvessel density for tumors of each
mouse presented in A. Three cases could not be counted, as no TSP-1 tumor could be detected (mice C9/1 and E7/5), or the tumor was too small to
be scored (C9/4). Between C and TSP-1 tumors, the difference in the mean number of microvessels was found to be highly significant (Student’s t test;
P , 0.0001, n 5 24).
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the decrease in the production levels of an angiogenesis in-
hibitor caused by low oxygen tension. We demonstrate
that anoxia can dramatically reduce the levels of TSP-1
production and that this occurs at the posttranscriptional
level. Posttranscriptional regulation is also one of the major
mechanisms accounting for hypoxia/anoxia-induced up-
regulation of VEGF (39). Recently, in human umbilical
vein endothelial cells, TSP-1 mRNA was shown to be sta-
bilized under hypoxia (40). This result might reflect differ-
ent functions of TSP-1 in different cell types. Upregulation
of TSP-1 in endothelial cells might function as a negative
feedback mechanism to prevent excessive angiogenesis in
physiological conditions of hypoxia. In contrast, downreg-
ulation of TSP-1 in tumor cells due to hypoxia might rep-
resent an early step to tilt the angiogenic balance in favor of
angiogenesis. Later in disease progression, more stable
changes due to genetic alterations such as LOH on chro-
mosome 10 might stabilize the angiogenic switch. These
results indicate that anoxia should be considered an impor-
tant process for tumor development for its direct action
both on the increase of angiogenic factors and the decrease
in inhibitor(s) of angiogenesis. These mechanisms should
prove to be important not only in tumor development but
also in other physiological and pathological conditions
linked to oxygen depletion.
We show that increased expression of TSP-1 in human
glioblastoma cells was able to markedly suppress subcutane-
ous tumor growth in athymic mice. Since TSP-1 is a potent
inhibitor of angiogenesis, we measured vessel density and
found an overall reduction of 52%. In tumors from TSP-1
gene–transfected cells, we mainly observed little capillaries,
whereas in control tumors the presence of large abnormal
vessels was predominant. This is consistent with the pri-
mary role of TSP-1 in determining endothelial cell pheno-
type and differentiation (25). However, since tumors arising
from TSP-1 clones were, in the majority of the cases, ex-
tremely small, we cannot exclude that reduced vessel num-
bers are a consequence rather than the cause of smaller size
tumors. Furthermore, it will be important to repeat these
experiments intracerebrally to evaluate whether TSP-1 can
also suppress glioma growth orthotopically.
Because we did not find any direct growth suppressing
effects of TSP-1 transfection in culture, the observed in
vivo suppression of tumor growth is most likely due to
other TSP-1 activities. Besides its effect on angiogenesis,
TSP-1 can modulate tumor cell adhesion and inhibit pro-
teases (17). TSP-1 expression was previously shown to in-
versely correlate with malignant progression in human lung
and breast carcinoma cell lines (41). Inhibition of angiogen-
esis and tumor growth has been observed in human breast
and skin carcinoma cell lines transfected with TSP-1 cDNA
(42, 43). Furthermore, TSP-1 overexpression has been
shown to suppress the tumorigenicity of transformed en-
dothelial cells (25). Opposite results were found in a human
squamous carcinoma, where reduction of TSP-1 expression
reversed the malignant phenotype (44), and in mouse sar-
coma and melanoma cells, where TSP-1 promoted tumor
cell metastasis (45, 46). The reasons for these apparently
discordant results are unclear at this stage. They may reflect
the presence of various TSP-1 receptors in diverse cell
types and/or different cell responses to different amounts of
TSP-1. Understanding the multiple functions of this large
protein and the molecular mechanisms regulating its ex-
pression in various tissues should help resolve this issue.
In conclusion, we demonstrate that in glioma cells, un-
like in fibroblasts, p53 does not regulate TSP-1 expression.
We show for the first time that anoxia can reduce the ex-
pression of the angiogenesis inhibitor TSP-1. Thus, de-
creased oxygen tension associated with pathological condi-
tions such as cancer can promote angiogenesis by affecting
the regulation of both angiogenesis stimulators and inhibi-
tors. Finally, demonstrating that increased expression of
TSP-1 by two- to 28-fold suppresses tumorigenicity of
glioblastoma cells in an animal model indicates that even a
modest reduction in TSP-1 production might be relevant
to human tumor progression. These results suggest that the
ability of TSP-1 to restrain tumor growth might be ex-
ploited therapeutically, especially in glioblastoma where the
possibilities for surgical intervention are often limited.
Figure 6. Immunostaining for vessels in tumors from mouse C8/9
using anti-CD31 antibody. (a) Control tumor. (b) TSP-1 tumor. Arrows
indicate vessels and capillaries.
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